CC BY-NC-ND 4.0 · Laryngorhinootologie 2018; 97(S 02): S96
DOI: 10.1055/s-0038-1640043
Abstracts
Onkologie: Oncology

Palliative treatment of head and neck squamous cell carcinoma (HNSCC) patients in the clinical daily practice; a retrospective analysis

M Hezel
1   Universitätsklinikum Hamburg-Eppendorf – HNO, Hamburg, Deutschland
,
S Sehner
2   UKE – Zentrum für Experimentelle Medizin Institut für Medizinische Biometrie und, Hamburg
,
N Möckelmann
3   UKE – HNO, Hamburg
,
P Schafhausen
4   UKE – Medizinische Klinik II/Onkologie, Hamburg
,
A Münscher
3   UKE – HNO, Hamburg
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
 
 

    Introduction:

    Whereas the EXTREME-protocol has shown significant survival outcome, many patients in our daily practice are not fit enough and need alternative treatment regiments. We investigated overall survival, time to treatment failure and causes of death in patients who received palliative treatment in our clinic.

    Method:

    retrospective analysis.

    Results:

    154 patients were treated between 2010 and 2015 and 47.8% (24.8%) were alive after 12 month (24 m). Median overall survival (OS) was 11.7 m. 42 received best supportive care (BSC), 39 EXTREME-protocol and 73 patients other systemic therapy. OS in EXTREME was 16.1 m, BSC 2.6 m, and with other treatments 14.5 m (p < 0.001; HR BSC: 2.29; HR other 0.9). Median time to treatment failure (TTF) under EXTREME was 6.4 m, BSC 2.5 m and with others 5.1 m (p = 0.005; HR BSC: 0.48; HR other 0.24). OS und TTF between EXTREME and others were not stat. significant. The cause of death was in 19.2% tumor related, in 6.6% therapy related, and in 29.8% not classified. In 44.4% cause of death was unknown. In 2.7% death was related to EXTREME and in 3.9% related to other treatments.

    Conclusion:

    The results of OS and TTF that we find in a controlled setting of a clinical trial are not always reproducible. Only part of the patients can complete the recommended first line treatment standard of a recurrent/metastatic situation. Furthermore occurred therapy related deaths. Our results show once more the importance of an interdisciplinary approach and an individual selection of therapies per patient.


    #

    No conflict of interest has been declared by the author(s).

    Dr Marcus Hezel
    UKE-Hamburg,
    Martinistr. 52, 20246,
    Hamburg,
    Deutschland   

    Publikationsverlauf

    Publikationsdatum:
    18. April 2018 (online)

    © 2018. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Stuttgart · New York